Stock Track | Recursion Pharmaceuticals Soars 5% Pre-Market on CEO Transition and $30M Milestone Achievement

Stock Track

Nov 05

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) jumped 5% in pre-market trading on Wednesday, following a series of positive announcements that overshadowed a revenue miss in its third-quarter results.

The clinical-stage TechBio company revealed a leadership transition plan, with current Chief R&D and Commercial Officer Najat Khan, Ph.D., set to succeed Co-Founder Chris Gibson, Ph.D., as CEO and President, effective January 1, 2026. This strategic move aims to drive the next phase of growth for Recursion, leveraging Dr. Khan's expertise in integrating scientific discovery, data technology, and business strategy.

Adding to the optimism, Recursion announced the achievement of a $30 million milestone payment from its collaboration with Roche and Genentech. This payment, triggered by the delivery of a whole-genome map of microglial immune cells, brings the total upfront and milestone payments from partners to over $500 million. The company also reported a strong cash position of approximately $785 million as of October 9, 2025, providing a runway through the end of 2027 without additional financing.

Despite reporting lower-than-expected Q3 revenue of $5.2 million compared to analysts' estimates of $17 million, investors appear to be focusing on Recursion's progress in its clinical programs and pipeline development. The company highlighted advancements in several key programs, including REC-617 for cancer treatment and REC-7735, a new development candidate for PI3Kα H1047R inhibition.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1155049623"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155049623\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155049623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155049623","market":"us","top_or_hot":-1,"title":"Stock Track | Recursion Pharmaceuticals Soars 5% Pre-Market on CEO Transition and $30M Milestone Achievement","media":"Stock Track","content":"<p>Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) jumped 5% in pre-market trading on Wednesday, following a series of positive announcements that overshadowed a revenue miss in its third-quarter results.</p>\n\n<p>The clinical-stage TechBio company revealed a leadership transition plan, with current Chief R&D and Commercial Officer Najat Khan, Ph.D., set to succeed Co-Founder Chris Gibson, Ph.D., as CEO and President, effective January 1, 2026. This strategic move aims to drive the next phase of growth for Recursion, leveraging Dr. Khan's expertise in integrating scientific discovery, data technology, and business strategy.</p>\n\n<p>Adding to the optimism, Recursion announced the achievement of a $30 million milestone payment from its collaboration with Roche and Genentech. This payment, triggered by the delivery of a whole-genome map of microglial immune cells, brings the total upfront and milestone payments from partners to over $500 million. The company also reported a strong cash position of approximately $785 million as of October 9, 2025, providing a runway through the end of 2027 without additional financing.</p>\n\n<p>Despite reporting lower-than-expected Q3 revenue of $5.2 million compared to analysts' estimates of $17 million, investors appear to be focusing on Recursion's progress in its clinical programs and pipeline development. The company highlighted advancements in several key programs, including REC-617 for cancer treatment and REC-7735, a new development candidate for PI3Kα H1047R inhibition.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Recursion Pharmaceuticals Soars 5% Pre-Market on CEO Transition and $30M Milestone Achievement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Recursion Pharmaceuticals Soars 5% Pre-Market on CEO Transition and $30M Milestone Achievement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) jumped 5% in pre-market trading on Wednesday, following a series of positive announcements that overshadowed a revenue miss in its third-quarter results.</p>\n\n<p>The clinical-stage TechBio company revealed a leadership transition plan, with current Chief R&D and Commercial Officer Najat Khan, Ph.D., set to succeed Co-Founder Chris Gibson, Ph.D., as CEO and President, effective January 1, 2026. This strategic move aims to drive the next phase of growth for Recursion, leveraging Dr. Khan's expertise in integrating scientific discovery, data technology, and business strategy.</p>\n\n<p>Adding to the optimism, Recursion announced the achievement of a $30 million milestone payment from its collaboration with Roche and Genentech. This payment, triggered by the delivery of a whole-genome map of microglial immune cells, brings the total upfront and milestone payments from partners to over $500 million. The company also reported a strong cash position of approximately $785 million as of October 9, 2025, providing a runway through the end of 2027 without additional financing.</p>\n\n<p>Despite reporting lower-than-expected Q3 revenue of $5.2 million compared to analysts' estimates of $17 million, investors appear to be focusing on Recursion's progress in its clinical programs and pipeline development. The company highlighted advancements in several key programs, including REC-617 for cancer treatment and REC-7735, a new development candidate for PI3Kα H1047R inhibition.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1155049623","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155049623","pubTimestamp":1762350088,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) jumped 5% in pre-market trading on Wednesday, following a series of positive announcements that overshadowed a revenue miss in its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"个股追踪|Recursion Pharmaceuticals因CEO换届和3000万美元里程碑成就盘前飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) jumped 5% in pre-market trading on Wednesday, following a series of positive announcements that overshadowed a revenue miss in its third-quarter results.\nThe clinical-stage TechBio company revealed a leadership transition plan, with current Chief R&D and Commercial Officer Najat Khan, Ph.D., set to succeed Co-Founder Chris Gibson, Ph.D., as CEO and President, effective January 1, 2026. This strategic move aims to drive the next phase of growth for Recursion, leveraging Dr. Khan's expertise in integrating scientific discovery, data technology, and business strategy.\nAdding to the optimism, Recursion announced the achievement of a $30 million milestone payment from its collaboration with Roche and Genentech. This payment, triggered by the delivery of a whole-genome map of microglial immune cells, brings the total upfront and milestone payments from partners to over $500 million. The company also reported a strong cash position of approximately $785 million as of October 9, 2025, providing a runway through the end of 2027 without additional financing.\nDespite reporting lower-than-expected Q3 revenue of $5.2 million compared to analysts' estimates of $17 million, investors appear to be focusing on Recursion's progress in its clinical programs and pipeline development. The company highlighted advancements in several key programs, including REC-617 for cancer treatment and REC-7735, a new development candidate for PI3Kα H1047R inhibition.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}